Tissue Regenix Group PLC Director/PDMR Shareholding (1486Y)
11 May 2021 - 4:00PM
UK Regulatory
TIDMTRX
RNS Number : 1486Y
Tissue Regenix Group PLC
11 May 2021
Tissue Regenix Group plc
("Tissue Regenix" or "the Group")
Director/PDMR Shareholding
Tissue Regenix (AIM: TRX), the regenerative medical devices
company, announces that on 10 May 2021, Daniel Lee, Chief Executive
Officer, acquired 2,068,750 Ordinary Shares in the Group at a price
of 0.69 pence per share for a total consideration of
GBP14,274.38.
As a result, Daniel Lee's beneficial interest in the Company is
2,068,750 Ordinary Shares, representing 0.03% of the total issued
share capital.
For more information:
Tissue Regenix Group plc www.tissueregenix.com
David Cocke, Chief Financial Officer Via Walbrook PR
Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44(0)20 7710 7600
and Broker)
Ben Maddison / Alex Price
Walbrook PR Ltd Tel: +44 (0)20 7933 8780
Alice Woodings / Paul McManus TissueRegenix@walbrookpr.com
About Tissue Regenix ( www.tissueregenix.com )
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human soft tissue leaving an acellular tissue
scaffold which is not rejected by the patient's body and can then
be used to repair diseased or worn-out body parts. Current
applications address many critical clinical needs such as sports
medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight
Technologies(R), a biotech company that specializes in regenerative
medicine and is dedicated to the development of innovative
osteoinductive and soft tissue scaffolds that enhance healing
opportunities of defects created by trauma and disease. CellRight's
human osteobiologics may be used in spine, trauma, general
orthopaedic, foot & ankle, dental, and sports medicine surgical
procedures.
The information contained in this notification is disclosed in
accordance with the requirements of the EU Market Abuse Regulation
as it forms part of UK law by virtue of the European Union
(Withdrawal) Act 2018. The notification form is set out below.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Daniel Lee
------------------------ --------------------------------------
2 Reason for the notification
----------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
------------------------ --------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------
a) Name Tissue Regenix Group plc
------------------------ --------------------------------------
b) LEI 213800PNOD5UHQUFJI36
------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
----------------------------------------------------------------
a) Description Ordinary Shares of 0.1p each
of the financial
instrument,
type of instrument
------------------------ --------------------------------------
b) Identification GB00B5SGVL29
code
------------------------ --------------------------------------
c) Nature of the Acquisition of Ordinary Shares
transaction
------------------------ --------------------------------------
d) Price(s) and Price Volume
volume(s) 0.69p 2,068,750
----------
------------------------ --------------------------------------
d) Aggregated 2,068,750
information GBP14,274.38
- Aggregated
volume
- Price
------------------------ --------------------------------------
e) Date of the 10 May 2021
transaction
------------------------ --------------------------------------
f) Place of the London Stock Exchange, AIM Market
transaction
------------------------ --------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBCGDUCSBDGBG
(END) Dow Jones Newswires
May 11, 2021 02:00 ET (06:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2024 to May 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2023 to May 2024